- Conditions
- Rectal Cancer, Colon Cancer, Colonic Neoplasms, Anal Cancer
- Interventions
- genetic analysis
- Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2017
- U.S. locations
- 1
- States / cities
- Stanford, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 218
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck, Cancer of Rectum, Cancer of Kidney, Cancer of Esophagus, Cancer of Colon, Cancer Skin, Cancer of Cervix, Cancer, Metastatic, Cancer of Larynx, Cancer of Neck, Cancer of Lung, Cancer of Brain and Nervous System, Cancer of Vulva, Disseminated, Cancer of Pancreas, Sarcoma, GIST, Small-cell Lung Cancer, Adenocarcinoma Lung, Cancer of Prostate, Cancer, Advanced, Adrenal Cancer, Testicular Cancer, Uterine Cancer, Bronchoalveolar Cell Lung Cancer, Cancer Unknown Primary, Glioblastoma Multiforme, Oligodendroglioma, Breast Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma, Cholangiocarcinoma, Squamous Cell Carcinoma, Transitional Cell Carcinoma, Cancer, Other, Cancer, Anal, Melanoma, Cancer, Bile Duct, Cancer, Bladder, Cancer Cords Vocal, Cancers Cell Neuroendocrine, Cancer Differentiated Poorly, Cancer, Anaplastic Thyroid
- Interventions
- Not listed
- Lead sponsor
- SpeciCare
- Industry
- Eligibility
- 1 Month to 99 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Gainesville, Georgia
- Conditions
- Carcinomas, Amyloidosis, Anal Cancer, Anemia, Cholangiocarcinoma of the Extrahepatic Bile Duct, Transitional Cell Carcinoma of Bladder, Bone Marrow Transplant Failure, Bone Cancer, Cancer of Brain and Nervous System, Breast Cancer, Carcinoma of the Large Intestine, Endocrine Cancer, Esophageal Cancer, Eye Cancer, Gall Bladder Cancer, Gastric (Stomach) Cancer, Gastrooesophageal Cancer, Gastrointestinal Stromal Tumor (GIST), Gynecologic Cancers, Head and Neck Cancers, Hepatobiliary Neoplasm, Kidney (Renal Cell) Cancer, Leukemia, Lung Cancer, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mesothelioma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Neuroendocrine Tumors, Myeloproliferative Disorders, Pancreatic Cancer, Prostate Cancer, Skin Cancer, Soft Tissue Sarcoma, Testicular Cancer, Thymus Cancer, Thyroid Cancer
- Interventions
- Not listed
- Lead sponsor
- Daniel Bernstein
- Other
- Eligibility
- Up to 40 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Anal Cancer, Precancerous Condition
- Interventions
- cidofovir, DNA methylation analysis, gene expression analysis, polymerase chain reaction, biopsy, histopathologic examination
- Drug · Genetic · Procedure
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 8
- States / cities
- Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
- Conditions
- Anal Cancer
- Interventions
- Radiation (reduced elective nodal dose (30.6 Gy), Capecitabine, Mitomycin c
- Radiation · Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 3
- States / cities
- Cincinnati, Ohio • Columbus, Ohio • Burlington, Vermont
- Conditions
- Cancer
- Interventions
- capecitabine, irinotecan hydrochloride
- Drug
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2003
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Cancer
- Interventions
- aminocamptothecin colloidal dispersion
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Rectal Cancer, Rectal Tumor, Rectal/Anal
- Interventions
- CG-100 intraluminal bypass device, Stoma
- Device · Procedure
- Lead sponsor
- Colospan Ltd.
- Industry
- Eligibility
- 22 Years to 70 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 6
- States / cities
- Irvine, California • San Diego, California • Aurora, Colorado + 3 more
- Conditions
- Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Castration Resistant Prostate Cancer, Colorectal Cancer, Gastric/ Gastroesophageal Junction, Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Squamous Carcinoma of the Anal Canal
- Interventions
- INCB106385, INCMGA00012
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 8
- States / cities
- West Hollywood, California • Baltimore, Maryland • Boston, Massachusetts + 5 more
- Conditions
- Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Liver Cancer, Pancreatic Cancer, Small Intestine Cancer
- Interventions
- irinotecan hydrochloride, oxaliplatin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2002
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, Advanced Bladder Carcinoma, Advanced Breast Carcinoma, Advanced Carcinoid Tumor, Advanced Cervical Carcinoma, Advanced Colorectal Carcinoma, Advanced Gastric Carcinoma, Advanced Glioblastoma, Advanced Head and Neck Carcinoma, Advanced HER2 Positive Breast Carcinoma, Advanced Lung Carcinoma, Advanced Lung Small Cell Carcinoma, Advanced Malignant Germ Cell Tumor, Advanced Malignant Solid Neoplasm, Advanced Neuroendocrine Carcinoma, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Small Cell Neuroendocrine Carcinoma, Advanced Prostate Carcinoma, Hematopoietic and Lymphoid System Neoplasm, Multiple Myeloma, Myelodysplastic Syndrome, Advanced Basal Cell Carcinoma, Advanced Cholangiocarcinoma, Advanced Endometrial Carcinoma, Advanced Esophageal Carcinoma, Advanced Fallopian Tube Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Liver Carcinoma, Advanced Lymphoma, Advanced Malignant Testicular Neoplasm, Advanced Melanoma, Advanced Merkel Cell Carcinoma, Advanced Penile Carcinoma, Advanced Primary Malignant Central Nervous System Neoplasm, Advanced Renal Cell Carcinoma, Advanced Sarcoma, Advanced Skin Squamous Cell Carcinoma, Advanced Urethral Carcinoma, Advanced Vaginal Carcinoma, Advanced Vulvar Carcinoma, Advanced Appendix Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma
- Interventions
- Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Grand Forks, North Dakota
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix, Distal Urethral Cancer, Fallopian Tube Cancer, Gastrinoma, Glucagonoma, Inflammatory Breast Cancer, Insulinoma, Liver Metastases, Localized Unresectable Adult Primary Liver Cancer, Lung Metastases, Male Breast Cancer, Malignant Pericardial Effusion, Malignant Pleural Effusion, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Parathyroid Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Newly Diagnosed Carcinoma of Unknown Primary, Occult Non-small Cell Lung Cancer, Pancreatic Polypeptide Tumor, Primary Peritoneal Cavity Cancer, Proximal Urethral Cancer, Pulmonary Carcinoid Tumor, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adrenocortical Carcinoma, Recurrent Adult Primary Liver Cancer, Recurrent Anal Cancer, Recurrent Bladder Cancer, Recurrent Breast Cancer, Recurrent Carcinoma of Unknown Primary, Recurrent Cervical Cancer, Recurrent Colon Cancer, Recurrent Endometrial Carcinoma, Recurrent Esophageal Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Pancreatic Cancer, Recurrent Parathyroid Cancer, Recurrent Prostate Cancer, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer, Recurrent Salivary Gland Cancer, Recurrent Small Intestine Cancer, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Thyroid Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer, Skin Metastases, Small Intestine Adenocarcinoma, Somatostatinoma, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Adrenocortical Carcinoma, Stage III Bladder Cancer, Stage III Cervical Cancer, Stage III Colon Cancer, Stage III Endometrial Carcinoma, Stage III Esophageal Cancer, Stage III Follicular Thyroid Cancer, Stage III Gastric Cancer, Stage III Malignant Testicular Germ Cell Tumor, Stage III Mucoepidermoid Carcinoma of the Oral Cavity, Stage III Ovarian Epithelial Cancer, Stage III Pancreatic Cancer, Stage III Papillary Thyroid Cancer, Stage III Prostate Cancer, Stage III Rectal Cancer, Stage III Renal Cell Cancer, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Vaginal Cancer, Stage III Vulvar Cancer, Stage IIIA Anal Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Anal Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Adrenocortical Carcinoma, Stage IV Anal Cancer, Stage IV Bladder Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Endometrial Carcinoma, Stage IV Esophageal Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Gastric Cancer, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Pancreatic Cancer, Stage IV Papillary Thyroid Cancer, Stage IV Prostate Cancer, Stage IV Rectal Cancer, Stage IV Renal Cell Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Stage IVB Vulvar Cancer, Thyroid Gland Medullary Carcinoma, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer, Urethral Cancer Associated With Invasive Bladder Cancer, WDHA Syndrome
- Interventions
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Cervical Cancer, Anal Cancer, Penile Cancer
- Interventions
- Personalized Chatbot Intervention, Non-Personalized Chatbot Intervention, No Chatbot Control
- Behavioral
- Lead sponsor
- University of Maryland, College Park
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 456 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- College Park, Maryland
- Conditions
- Solid Tumors With PTCH1 Loss-of-function Mutations
- Interventions
- ENV-101 (taladegib)
- Drug
- Lead sponsor
- Endeavor Biomedicines, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Santa Rosa, California • Tampa, Florida + 13 more
- Conditions
- Anal High-Grade Squamous Intraepithelial Lesions
- Interventions
- Assessment of Health-Related Quality
- Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 35 Years and older
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 4
- States / cities
- Evanston, Illinois • New York, New York
- Conditions
- Colon Polyps, Colonic Dysplasia, Anal Dysplasia
- Interventions
- Proflavine Hemisulfate
- Drug
- Lead sponsor
- Anandasabapathy, Sharmila, M.D.
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Squamous Cell Carcinoma of the Anus
- Interventions
- Cisplatin, 5-Fluorouracil (5-FU), Carboplatin, Paclitaxel
- Drug
- Lead sponsor
- Royal Marsden NHS Foundation Trust
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Anal Cancer, Nonneoplastic Condition, Precancerous Condition
- Interventions
- Papanicolaou test
- Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma, Stage IV Gastric Cancer, Stage IV Adenocarcinoma of the Gastroesophageal Junction, Stage IVA Esophageal Adenocarcinoma, Stage IVA Esophageal Squamous Cell Carcinoma, Stage IVA Gastric Cancer, Stage IVA Adenocarcinoma of the Gastroesophageal Junction, Stage IVB Esophageal Adenocarcinoma, Stage IVB Esophageal Squamous Cell Carcinoma, Stage IVB Gastric Cancer, Stage IVB Gastroesophageal Junction Adenocarcinoma, Metastatic Anal Canal Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Malignant Digestive System Neoplasm, Metastatic Small Intestinal Carcinoma, Pancreatobiliary Carcinoma, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC V8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Anal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Stage IVC Colorectal Cancer AJCC v8
- Interventions
- Radiation Therapy (RT)
- Radiation
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 2
- States / cities
- San Francisco, California • Walnut Creek, California
- Conditions
- Rectal Cancer, Colon Cancer, Anal Cancer
- Interventions
- Questionnaire
- Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- High Grade Anal Canal Intraepithelial Neoplasia, High Grade Vulvar Squamous Intraepithelial Lesion
- Interventions
- Laboratory Biomarker Analysis, Placebo Administration, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine
- Other · Biological
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 27 Years to 69 Years
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Seattle, Washington
- Conditions
- Neoplasms, Lung Neoplasms, Colon Neoplasms, Breast Neoplasms, Pancreatic Neoplasms, Prostate Neoplasms, Kidney Neoplasms, Liver Neoplasms, Rectal Neoplasms, Hematologic Neoplasms, Multiple Myeloma, Myelodysplastic Syndromes, Ovarian Neoplasms, Bladder Neoplasms, Testicular Neoplasms, Endometrial Neoplasms, Brain Neoplasms, Biliary Tract Neoplasms, Head and Neck Neoplasms, Uterine Cervical Neoplasms, Skin Neoplasms, Melanoma, Gastric Neoplasms, Anal Neoplasms, Sarcoma
- Interventions
- Provider determined
- Other
- Lead sponsor
- CureOne
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Idaho Falls, Idaho
- Conditions
- Pancreatic Cancer, Gastrointestinal Neoplasms, Colon Rectal Cancer Adenocarcinoma, Esophageal Cancer, Gall Bladder Cancer, Gastric (Stomach) Cancer, Gastrooesophageal Cancer, Gastrointestinal Stromal Tumor (GIST), Hepatobiliary Neoplasm, Liver Carcinoma, Gallbladder Carcinoma, Bile Duct Carcinoma, Carcinoma of the Large Intestine, Anal Cancer
- Interventions
- Observation
- Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Adult Solid Tumor
- Interventions
- SQZ-eAPC-HPV, Pembrolizumab
- Biological
- Lead sponsor
- SQZ Biotechnologies
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • Duarte, California • Aurora, Colorado + 5 more